Conversely, the TREM2‐agonist monoclonal antibody AL002c increases microglial efferocytosis, enhances Aβ clearance, dampens neuroinflammation, and improves cognition in AD mouse models [163]. Here, TREM2 is linked to Alzheimer disease.